Menu
Recruiting NCT04324151

Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC

— Observational Non Small Cell Lung Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Non Small Cell Lung Cancer. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

Overview

This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

Detailed description

Inclusion criteria:

diagnosed with Non-small cell lung cancer EGFR and ALK and ROS1 negative Treatment naive Potentially Resectable identified by MDT

Primary outcome measures

  • PFS [Time frame: may 2020- may 2021 (1 year)]
Secondary outcome measures (2)
  • OS [Time frame: may 2020- may 2021 (1 year)]
  • ORR [Time frame: may 2020- may 2021 (1 year)]

Eligibility criteria

Inclusion criteria

  • ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
  • Potentially Resectable NSCLC
  • Treatment Plan is Crizotinb or Standard Chemotherapy

Exclusion criteria

  • Patients with contraindication of chemotherapy
  • Pregnant or breast feeding women

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 1 center
  • Yongchang Zhang — Changsha

Identifiers

NCT: NCT04324151 · PERSPECT

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗